Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Type 3 immune response defined by increased IL-22 production drives fibrosis during chronic liver injury via enhanced TGF-β signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A exhibited similar pro-fibrotic activity in both animal studies and in human cells124,125”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [125]
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Reciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982 · cited 3×
“3, eaar7754 (2018) 26 October 2018 12 of 15 TGF- is essential for the differentiation of both TH17 and Tregs (42) and given the reported plasticity between these two cell subsets (19), it is possible that liver inflammation mediated by TNF-, IL-1, and IL-6 indirectly promotes differentiation of Tregs into TH17 cells a…”
BackgroundInfluentialPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809 · cited 3×
“Transforming growth factor– (TGF-) signaling is the key fibrogenic signal that activates hepatic stellate cells (HSCs), the main producer of extracellular matrix in the liver, and is modulated by proinflammatory mediators such as cytokines that act on HSCs and liver immune cells (1).”
BackgroundInfluentialThe aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055 · cited 2×
“Type 2 inflammation, characterized by production of IL-4, IL-5, IL-10, IL-13, IL-25, and IL-33, is associated with reduced hepatic inflammation but correlates with progression of liver fibrosis (4).”
BackgroundTh17 and regulatory T cell balance in autoimmune and inflammatory diseases
Noack, M., & Miossec, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.12.004 · Cited by 932 · cited 4×
“The ratio between Tregs and other inflammatory cells is one of the key determinants of the progression of inflammatory diseases (18).”
BackgroundInfluentialMast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906 · cited 1×
“IL-17–producing mast cells are associated with disease progression in rheumatoid arthritis and psoriasis (40, 41), suggesting that they may have a similar function in the liver.”
BackgroundThe 3 major types of innate and adaptive cell-mediated effector immunity
Annunziato, F., Romagnani, C., & Romagnani, S. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.001 · Cited by 818 · cited 2×
“The inflammatory response can be divided into three types (2).”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 1×
“Although TH17 cells were not the principal source of IL-17 in situ, they may enhance recruitment of innate effectors through induction of proinflammatory chemokines by endothelial cells (7).”
Backgroundthe Immunological Genome Consortium, Robinette, M. L., Fuchs, A., Cortez, V. S., Lee, J. S., Wang, Y., Durum, S. K., Gilfillan, S., & Colonna, M. (2015) · Nature Immunology · doi:10.1038/ni.3094 · Cited by 641
Zenewicz, L. A., Yancopoulos, G. D., Valenzuela, D. M., Murphy, A. J., Karow, M., & Flavell, R. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.023 · Cited by 628 · cited 2×
“There was no significant difference in serum ALT levels between IL-22RA1 KO and WT treated mice, suggesting that IL-22 does not exert hepatoprotective functions in this chronic injury model as previously reported during acute injury (11).”
BackgroundRadaeva, S., Sun, R., Pan, H.-N., Hong, F., & Gao, B. (2004) · Hepatology · doi:10.1002/hep.20184 · Cited by 597
Huber, S., Gagliani, N., Esplugues, E., O'Connor, W., Huber, F. J., Chaudhry, A., Kamanaka, M., Kobayashi, Y., Booth, C. J., Rudensky, A. Y., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.020 · Cited by 583
Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice
Kong, X., Feng, D., Wang, H., Hong, F., Bertola, A., Wang, F.-S., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.25744 · Cited by 448 · cited 3×
“(14) that used a liver-specific transgenic mouse model, where IL-22 levels were high and IL-22 signaling was most likely directed to hepatocytes that might not be physiological.”
BackgroundResultThe interleukin-17 pathway is involved in human alcoholic liver disease # †
Lemmers, A., Moreno, C., Gustot, T., Maréchal, R., Degré, D., Demetter, P., de Nadai, P., Geerts, A., Quertinmont, E., Vercruysse, V., et al. (2009) · Hepatology · doi:10.1002/hep.22680 · Cited by 394
Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A
Sonnenberg, G. F., Nair, M. G., Kirn, T. J., Zaph, C., Fouser, L. A., & Artis, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092054 · Cited by 380 · cited 1×
“The balance between IL-17A and IL-22 also contributes to pathogenesis, but the molecular mechanisms are unknown (15).”
BackgroundCutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium
Hueber, A. J., Asquith, D. L., Miller, A. M., Reilly, J., Kerr, S., Leipe, J., Melendez, A. J., & McInnes, I. B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903566 · Cited by 358
Tan, Z., Qian, X., Jiang, R., Liu, Q., Wang, Y., Chen, C., Wang, X., Ryffel, B., & Sun, B. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203013 · Cited by 330 · cited 1×
“IL-17–producing neutrophils were already reported to be profibrogenic during experimental hepatitis and in one cohort of HCV-infected patients (30, 38).”
BackgroundInterleukin-22 promotes human hepatocellular carcinoma by activation of STAT3
Jiang, R., Tan, Z., Deng, L., Chen, Y., Xia, Y., Gao, Y., Wang, X., & Sun, B. (2011) · Hepatology · doi:10.1002/hep.24486 · Cited by 310
Baroni, G. S., D’Ambrosio, L., Curto, P., Casini, A., Mancini, R., Jezequel, A. M., & Benedetti, A. (1996) · Hepatology · doi:10.1002/hep.510230538 · Cited by 295 · cited 1×
“Type 1 inflammation, characterized by production of interleukin-1 (IL-1), IL-6, tumor necrosis factor– (TNF-), and interferon- (IFN-), is proinflammatory and correlates with liver inflammation but is antifibrogenic (3, 4).”
BackgroundLouis, H., Van Laethem, J.-L., Wu, W., Quertinmont, E., Degraef, C., Van den Berg, K., Demols, A., Goldman, M., Le Moine, O., Geerts, A., et al. (1998) · Hepatology · doi:10.1002/hep.510280621 · Cited by 255
Withers, D. R., Hepworth, M. R., Wang, X., Mackley, E. C., Halford, E. E., Dutton, E. E., Marriott, C. L., Brucklacher-Waldert, V., Veldhoen, M., Kelsen, J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4046 · Cited by 243
Zhao, L., Tang, Y., You, Z., Wang, Q., Liang, S., Han, X., Qiu, D., Wei, J., Liu, Y., Shen, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018909 · Cited by 227
Konkel, J. E., Zhang, D., Zanvit, P., Chia, C., Zangarle-Murray, T., Jin, W., Wang, S., & Chen, W. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.015 · Cited by 220
Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice
Montaldo, E., Juelke, K., & Romagnani, C. (2015) · European Journal of Immunology · doi:10.1002/eji.201545598 · Cited by 190
Zhao, J., Zhang, Z., Luan, Y., Zou, Z., Sun, Y., Li, Y., Jin, L., Zhou, C., Fu, J., Gao, B., et al. (2014) · Hepatology · doi:10.1002/hep.26916 · Cited by 174
Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26)
Bengsch, B., Seigel, B., Flecken, T., Wolanski, J., Blum, H. E., & Thimme, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103801 · Cited by 169
Lake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki, W. T., & Cherrington, N. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040592 · Cited by 167 · cited 4×
“To further validate that IL-17A, hereinafter termed IL-17, and IL-22 are common markers of liver fibrosis, we consulted publicly available microarray data comparing moderate and advanced fibrotic livers in two studies on NASH (26) and hepatitis C virus (HCV) (27), respectively.”
BackgroundInfluentialGalectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C
Kared, H., Fabre, T., Bédard, N., Bruneau, J., & Shoukry, N. H. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003422 · Cited by 165
Self-citationNotch signaling drives IL-22 secretion in CD4+T cells by stimulating the aryl hydrocarbon receptor
Alam, M. S., Maekawa, Y., Kitamura, A., Tanigaki, K., Yoshimoto, T., Kishihara, K., & Yasutomo, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911755107 · Cited by 158
Fabre, T., Kared, H., Friedman, S. L., & Shoukry, N. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400861 · Cited by 150
Self-citationXue, J., Zhao, Q., Sharma, V., Nguyen, L. P., Lee, Y. N., Pham, K. L., Edderkaoui, M., Pandol, S. J., Park, W., & Habtezion, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.064 · Cited by 146
Brockmann, L., Giannou, A., Gagliani, N., & Huber, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051033 · Cited by 144 · cited 2×
“Dysregulated type 3 immunity is associated with abnormal tissue repair, chronic inflammatory diseases, and cancer in the gut and the lung (5).”
BackgroundType 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β
Hart, K. M., Fabre, T., Sciurba, J. C., Gieseck, R. L., Borthwick, L. A., Vannella, K. M., Acciani, T. H., de Queiroz Prado, R., Thompson, R. W., White, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3694 · Cited by 143
Self-citationTedesco, D., Thapa, M., Chin, C. Y., Ge, Y., Gong, M., Li, J., Gumber, S., Speck, P., Elrod, E. J., Burd, E. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.019 · Cited by 137
The controversial role of mast cells in fibrosis
Bradding, P., & Pejler, G. (2018) · Immunological Reviews · doi:10.1111/imr.12626 · Cited by 129 · cited 1×
“Neutrophils and mast cells are implicated in the progression of fibrosis in many organs due to their capacity to secrete profibrogenic factors such as reactive oxygen species, LOXL2 TGF-, and platelet-derived growth factor (37).”
BackgroundArmbrust, T., Batusic, D. S., Ringe, B., & Ramadori, G. P. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80113-4 · Cited by 123 · cited 1×
“Mast cells have been associated with liver fibrosis progression, interact with HSCs, and are one of the “core” fibrogenic populations in the body (39).”
BackgroundIntrahepatic IL-8 producing Foxp3+CD4+ regulatory T cells and fibrogenesis in chronic hepatitis C
Langhans, B., Krämer, B., Louis, M., Nischalke, H. D., Hüneburg, R., Staratschek-Jox, A., Odenthal, M., Manekeller, S., Schepke, M., Kalff, J., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.011 · Cited by 89
B7-H1–expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets
Kuang, D.-M., Xiao, X., Zhao, Q., Chen, M.-M., Li, X.-F., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Wu, Y., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74381 · Cited by 82
Langhans, B., Alwan, A. W., Krämer, B., Glässner, A., Lutz, P. L., Strassburg, C. P., Nattermann, J., & Spengler, U. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.038 · Cited by 77
Xuemin, W., Tang, X., Gong, X., Albanis, E., Friedman, S. L., & Mao, Z. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.007 · Cited by 69 · cited 2×
“MEF-2 is a p38-dependent TF important for activation of HSCs and regulation of TGF- signaling (31, 49).”
BackgroundResultWu, L., Liu, S., Liu, Y., Guo, C., Li, H., Li, W., Jin, X., Zhang, K., Zhao, P., Wei, L. J., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.003 · Cited by 59
Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin
Hu, B.-L., Cheng, S., Lei, R., Lu, D., Luo, W., Qin, S., Zhou, Y., & Jiang, H.-X. (2016) · Scientific Reports · doi:10.1038/srep36436 · Cited by 53 · cited 1×
“Some studies reported that in vitro IL-22 induces senescence of HSCs through induction of p21 or -catenin after 24 hours but protects against apoptosis (14, 45).”
BackgroundYang, Y. J., Bae, M., Park, Y., Lee, Y., Pham, T. X., Rudraiah, S., Manautou, J. E., Koo, S. I., & Lee, J. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.003 · Cited by 48 · cited 1×
“MEF-2 is a p38-dependent TF important for activation of HSCs and regulation of TGF- signaling (31, 49).”
BackgroundA Protective Function of IL-22BP in Ischemia Reperfusion and Acetaminophen-Induced Liver Injury
Kleinschmidt, D., Giannou, A. D., McGee, H. M., Kempski, J., Steglich, B., Huber, F. J., Ernst, T. M., Shiri, A. M., Wegscheid, C., Tasika, E., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700587 · Cited by 44
Macek Jilkova, Z., Afzal, S., Marche, H., Decaens, T., Sturm, N., Jouvin‐Marche, E., Huard, B., & Marche, P. N. (2016) · Liver International · doi:10.1111/liv.13060 · Cited by 40
Type 3 cytokines in liver fibrosis and liver cancer
Molina, M. F., Abdelnabi, M. N., Fabre, T., & Shoukry, N. H. (2019) · Cytokine · doi:10.1016/j.cyto.2018.07.028 · Cited by 39 · cited 1×
“Whether IL-22 exerts pro- or antifibrogenic functions on HSCs is controversial (44).”
BackgroundSelf-citationZhang, L.-J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i12.1918 · Cited by 30 · cited 1×
“IL-10, a cytokine that can be produced by Tregs, induces apoptosis of activated HSC (20, 21).”
Backgroundp53 mediates density‐dependent growth arrest
Meerson, A., Milyavsky, M., & Rotter, V. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00027-4 · Cited by 25 · cited 1×
“It is also possible that increased proliferation of HSCs in response to IL-22 may cause them to reach cellular confluence by 24 hours and up-regulate cell cycle arrest molecules such as p21/p53 (48) that are then degraded by 48 hours.”
BackgroundMunshaw, S., Hwang, H. S., Torbenson, M. S., Quinn, J., Hansen, K. D., Astemborski, J. A., Mehta, S. H., Ray, S. C., Thomas, D. L., & Balagopal, A. (2012) · Hepatology · doi:10.1002/hep.25655 · Cited by 20
Tedesco, D., Thapa, M., Gumber, S., Elrod, E. J., Rahman, K., Ibegbu, C., Magliocca, J. F., Adams, A. B., Anania, F. A., & Grakoui, A. (2016) · Hepatology · doi:10.1002/hep.28894 · Cited by 12
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
“Also, inhibiting IL-22 or IL-17 production by aryl hydrocarbon receptor or RAR-related orphan receptor γ antagonists improved fibrosis [136].”
BackgroundHepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“T H 17 cells drive liver fibrosis via the production of IL-17 and IL-22, which stimulate transforming growth factor-β (TGFβ) production in the liver, enhance TGFβ signalling in HSCs, and induce the production of collagen by HSCs and pro-inflammatory cytokines by both HSCs and Kupffer cells 120–122 .”
Harrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8050467 · Cited by 501
“Hyun and coworkers highlighted the importance of microRNA (miR)-125b-bearing MSC-Exos which suppressed pro-fibrotic function of HSCs by impeding activation of Hedgehog/Smoothened signaling pathway in these cells [82].”
BackgroundInfluentialMechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
“Neutrophils and mast cells can also be a major producer of IL-17 in fibrotic liver.(41) IL-17 is a profibrogenic cytokine which stimulates HSCs to increase levels of collagen type I, a-SMA, and TGF-b by activating NF-jB and STAT3.”
Background
Metadata
- Authors
- Fabre, T., Molina, M. F., Soucy, G., Goulet, J.-P., Willems, B., Villeneuve, J.-P., Bilodeau, M., & Shoukry, N. H.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Caprion (Canada) (CA)
- Corresponding author
- Shoukry, Naglaa H.
- ORCID
- Venue
- Science Immunology
- Published
- 2018-10-26
- Volume
- 3
- Issue
- 28
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2898290288
- Cited by
- 155
- References
- 52
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 15 · 2019: 7 · 2018: 1
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (HEO-115696)
- Fonds de Recherche du Québec - Santé
- Canadian Liver Foundation (N/A)
- Fonds de recherche du Québec – Santé (FRQS) AIDS and Infectious Disease Network
- Canadian Network on Hepatitis C
- Novartis/Canadian Liver Foundation Hepatology Research Chair (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver fibrosis, IL-17A, IL-22, TGF-beta signaling, hepatic stellate cells, p38 MAPK, neutrophils, mast cells, IL-22RA1, aryl hydrocarbon receptor, chronic liver injury, thioacetamide, carbon tetrachloride
- MeSH terms
- Interleukin-22, Animals, Azo Compounds, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Interleukins, Liver Cirrhosis, Male, Mice, Inbred C57BL, Pyrazoles, Transforming Growth Factor beta, Mice, Knockout, Interleukin-17, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.